This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Menu
Follow UroToday
Centers of Excellence
Urologic Oncology
Left Group
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Kidney Cancer
Kidney Cancer Today
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Daniel George, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mCRPC Treatment
Charles Ryan, MD
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Neal Shore, MD, FACS
A Patient Journey
Alicia Morgans, MD, MPH
Charles J. Ryan, MD
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Transformative Evidence
mCRPC
CARD Trial
PROfound Study
mHSPC
ENZAMET Trial
nmCRPC
PROSPER Trial
Advanced Prostate Cancer
HERO Trial
Bladder Cancer
Bladder Cancer Detection
Videos
Conference Coverage and Experts Group
Interviews with Experts at Conferences
ASCO 2019
ASCO 2020
ASCO GU 2020
ESMO 2020
Exclusive Collaborations
APCCC 2019
LUGPA Annual Meeting 2019
PCF 2019
SNMMI Curriculum
UroToday Exclusives
A Step Towards Personalized Medicine: PSMA PET Imaging in Prostate Cancer
Book Club
Contemporary Treatment Strategies For Androgen Deprivation Therapy In Prostate Cancer
COVID-19 and Genitourinary Cancers Videos
Large Urology Group Practice Association (LUGPA)
Precision Medicine: PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Videos
Urologic Oncology
Bladder Cancer
Bladder Cancer
Bladder Cancer Expert Debates
Advanced Bladder Cancer
Non-Muscle Invasive Bladder Cancer
Kidney Cancer
Advanced Kidney Cancer
Renal Cancer
Prostate Cancer
Advances in Nuclear Medicine, PET, and Theranostics
Advanced Prostate Cancer
Cardiovascular Disease in Men with Prostate Cancer
CRPC with Bone Metastases
The Expert Voice
Imaging: Prostate Cancer
Localized Prostate Cancer
mCRPC
mHSPC
Molecular Diagnostics
Navigating Cancer
nmCRPC
The Patient Voice
Precision Medicine in Prostate Cancer
Prostate Cancer
Upper Tract Urothelial Tumors
Upper Tract Urothelial Carcinoma
Pelvic Health & Reconstruction
Bladder Health
Indwelling Catheters
Intermittent Catheters
Nocturia & Lower Urinary Tract Conditions
Endourology
Endourology Today
Endourology
Journals
Everyday Urology - Oncology Insights
From the Editor
Current Issue
Previous Issues
Prostate Cancer and Prostatic Diseases
From the Editor
Current Article
Previous Articles
Clinical Trials
Clinical Trials
Search Clinical Trials
From the Editor
Current Letter
Previous Letters
Conference Coverage
Advanced Prostate Cancer Consensus Conference (APCCC)
2019 APCCC Meeting
American Society of Clinical Oncology (ASCO)
2020 Virtual Education Program
2020 Annual Meeting
2020 ASCO GU Symposium
2019 Annual Meeting
2019 ASCO GU Symposium
American Urological Association (AUA)
2020 Annual Meeting
2019 Annual Meeting
ANZUP Mini Annual Scientific Meeting (ASM)
2020 Virtual Annual Meeting
Bladder Cancer Advocacy Network (BCAN)
2020 Think Tank Virtual Program
2019 Think Tank
Canadian Urological Association (CUA)
2019 CUOS Summit
Clinical Conference
2019 American College of Surgeons
EMUC
2020 Annual Meeting
European Association of Urology (EAU)
2020 Annual Congress
2019 Annual Congress
ESOU 2019
Enhanced Recovery After Surgery (ERAS)
2019 ERAS Annual Congress
European Society for Medical Oncology (ESMO)
2020 Virtual Congress
2019 Annual Congress
Global Society of Rare GU Tumors
2020 Meeting
International Bladder Cancer Network (IBCN)
2020 Annual Virtual Meeting
2019 Meeting
Prostate Cancer Academy
2020 Annual Meeting
Société Internationale d'Urologie (SIU)
2020 Annual Congress
2019 Annual Congress
Society of Nuclear Medicine and Molecular Imaging (SNMMI)
2019 Therapeutics Conference
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
2020 Congress
2019 Congress
Society of Urologic Oncology (SUO)
2020 Annual Meeting
2020 SUO - AUA Summer Webcast
2019 Annual Meeting
Targeted Alpha Therapy (TAT)
2019 Symposium
World Congress of Endourology and SWL (WCE)
2019 Annual Meeting
Articles
Urologic Oncology
Adrenal Diseases
Bladder Cancer
CRPC w/ Bone Metastases
Penile Cancer
Prostate Cancer
Renal Cancer
Testicular Cancer
Upper Tract Tumors
Investigative Urology
Men's Health
Androgen Deficiency
BPH
Erectile Dysfunction
Male Infertility
Peyronie’s Disease
Prostatitis
Vasectomy
Pelvic Health & Reconstruction
Fecal Incontinence
Fistula
GU Trauma & Reconstruction
Indwelling Catheters
Infections
Intermittent Catheters
Interstitial Cystitis
Neurogenic Bladder
Nocturia
Overactive Bladder
Pelvic Prolapse
Post-prostatectomy Incontinence
Stress Incontinence
Underactive Bladder
Urethral Strictures
Urinary Incontinence
Urinary Retention
Urinary Tract Infection – CAUTIs
Urologic Catheters
Endourology & Urolithiasis
Minimally Invasive Procedures
Stone Disease
Pediatric Urology
Pediatric Urology
COVID-19 and Genitourinary Cancers
COVID-19 and Genitourinary Cancers
Calendar
UroToday Home
Conference Highlights
ESMO 2019
ESMO 2019
Prostate Cancer
Kidney Cancer
Bladder Cancer
Testicular Cancer
ESMO 2019 Bladder Cancer
Viewing 1-20 of 31 articles
ESMO 2019: Invited Discussant: How Do the Results of IMvigor130 Change Things in Bladder Cancer?
ESMO 2019: Invited Discussant: IMvigor130: Phase III Study of Atezolizumab with or without Platinum-Based Chemotherapy in Previously Untreated Metastatic Urothelial Carcinoma
ESMO 2019: EV-103 Enfortumab Vedotin plus Pembrolizumab for Urothelial Carcinoma
ESMO 2019: Invited Discussant: Results of the IMVigor130 Study of Atezoluzumab as Monotherapy, or in Combination with Platinum Chemotherapy for Patients with Advanced or Metastatic Urothelial Carcinoma
ESMO 2019: Immune Therapy in Combination with Targeted Therapy
ESMO 2019: IMvigor130: Efficacy and Safety of Atezolizumab as Monotherapy or Combined with Platinum-based Chemotherapy vs Placebo + Platinum-based Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma
ESMO 2019: IMvigor130: Efficacy and Safety from a Phase 3 Study of Atezolizumab as Monotherapy or Combined with Platinum-based Chemotherapy vs Placebo + PBC in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma
ESMO 2019: IMvigor130: Efficacy and Safety from a Phase 3 Study of Atezolizumab as Monotherapy or Combined with Platinum-based Chemotherapy versus Chemotherapy alone in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma
ESMO 2019: The NABUCCO Study, Pre-operative Ipilimumab and Nivolumab in Locoregionally Advanced, Stage III, Urothelial Cancer
ESMO 2019: Invited Discussant: (904PD, 905PD, 906PD) NABUCCO (mUC), FGFR3 Alteration as a Predictor of Non-Response to Neoadjuvant Pembrolizumab (mUC), and Adjuvant Sunitinib in Patients with High-Risk (RCC)
ESMO 2019: Immune Therapy in Combination with Chemotherapy
ESMO 2019: Single Agent Immune Therapy and Immune Combinations
ESMO 2019: Erdatitinib versus Available Therapies in Advanced Urothelial Cancer: A Matching Adjusted Indirect Comparison
ESMO 2019: Hyperphosphatemia Due to Erdafitinib and Anti-tumor Activity Among Patients with Advanced Urothelial Cancer
ESMO 2019: Multiple-cohort Analysis Investigating FGFR3 Alteration as a Predictor of Non-response to Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer - A Medical Oncologist's Perspective
ESMO 2019: Pre-Operative Ipilimumab and Nivolumab in Locoregionally Advanced, Stage III, Urothelial Cancer - NABUCCO
ESMO 2019: FGFR3 Alteration as a Predictor of Non-Response to Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer
ESMO 2019: Multiple-cohort Analysis Investigating FGFR3 Alteration as A Predictor of Non-response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer
ESMO 2019: Pre-operative Ipilimumab and Nivolumab in Locoregionally Advanced, Stage III, Urothelial Cancer (NABUCCO)
ESMO 2019: Invited Discussant for EV-103: Initial Results of Enfortumab Vedotin plus Pembro and of BISCAY, an Adaptive, Biomarker Directed Platform study in Metastatic Urothelial Cancer
1
2
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free